Following 2Q14 (Dec) results, many analysts are reiterating a Hold rating. On one hand, the company was able to exceed 2Q14 guidance. However, the company is still unprofitable and is guiding 3Q14 results to include an even greater loss. At this time, the company has no clear path to profitability other than a 35%-40% increase…
Last night, GVP reported a good quarter, delivering contract revenue upside, in line GAAP EPS and relatively stable backlog in its 3Q13 earnings report. Despite posting a respectable performance, the company is still feeling the impact from stalled nuclear and non-nuclear simulator projects in the US, and from cancelled and delayed nuclear projects in Japan…
The Medicines Co (MDCO) announced that the U.S. District Court for the Northern District of Illinois has ruled in its favor in a patent infringement lawsuit against Mylan, Inc (MYL). Mylan was looking to get its generic version of The Medicines Co.’s Angiomax (European trade name: Angiox) approved in the U.S. The Medicines Co. stated…
Despite posting better-than-expected earnings, Biogen Idec’s (BIIB) shares fell 5.4% immediately after the release of third quarter results. Although shares recovered slightly in the subsequent trading session, the overall decline is approximately 3.3% since the announcement of third quarter results. The decline in share price reflects concerns regarding the growth prospects of Biogen’s oral multiple…
Biogen Idec (BIIB) reported third quarter 2014 earnings per share of $3.79 (including the impact of stock-based compensation expense), way above the Consensus Estimate of $3.22 and the year-ago earnings of $2.34 per share. Third quarter 2014 revenues increased 37% to $2.5 billion, topping the Consensus Estimate of $2.4 billion. Including one-time items, third quarter…
Amgen (AMGN) reported third quarter 2014 earnings of $2.30 per share, well above the Consensus Estimate of $2.06 and the year-ago earnings of $1.93. Earnings were driven by higher revenues and higher profitability on Enbrel. Total revenues increased 6% to $5,031 million in the third quarter of 2014, beating the Consensus Estimate of $4,918 million….
